SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 2004; 18: 9499.
  • 2
    Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931940.
  • 3
    Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004; 10: 301309.
  • 4
    Kendrick EA, McVicar JP, Kowdley KV, Bronner MP, Emond MJ, Alpers CE, et al. Renal disease in hepatitis C-positive liver transplant recipients. Transplantation 1997; 63: 12871293.
  • 5
    Morales JM, Campistol JM, Andres A, Rodicio JL. Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 1997; 6: 511515.
  • 6
    Nochy D, Callard P, Bellon B, Bariety J, Druet P. Association of overt glomerulonephritis and liver disease: a study of 34 patients. Clin Nephrol 1976; 6: 422427.
  • 7
    Crawford DH, Endre ZH, Axelsen RA, Lynch SV, Balderson GA, Strong RW, et al. Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am J Kidney Dis 1992; 19: 339344.
  • 8
    McGuire BM, Julian BA, Bynon JS Jr, Cook WJ, King SJ, Curtis JJ, et al. Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144: 735741.
  • 9
    McCauley J, Van Thiel DH, Starzl TE, Puschett JB. Acute and chronic renal failure in liver transplantation. Nephron 1990; 55: 121128.
  • 10
    Rimola A, Gavaler JS, Schade RR, el-Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology 1987; 93: 148156.
  • 11
    Cabezuelo JB, Ramirez P, Rios A, Acosta F, Torres D, Sansano T, et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006; 69: 10731080.
  • 12
    Gainza FJ, Valdivieso A, Quintanilla N, Errazti G, Gastaca M, Campo M, et al. Evaluation of acute renal failure in the liver transplantation perioperative period: incidence and impact. Transplant Proc 2002; 34: 250251.
  • 13
    Lima EQ, Zanetta DM, Castro I, Massarollo PC, Mies S, Machado MM, Yu L. Risk factors for development of acute renal failure after liver transplantation. Ren Fail 2003; 25: 553560.
  • 14
    O'Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant 2007; 7: 168176.
  • 15
    Sanchez EQ, Gonwa TA, Levy MF, Goldstein RM, Mai ML, Hays SR, et al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Transplantation 2004; 78: 10481054.
  • 16
    Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204R212.
  • 17
    Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
  • 18
    Zaltzman JS, Pei Y, Maurer J, Patterson A, Cattran DC. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 1992; 54: 875878.
  • 19
    Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66: 5966.
  • 20
    Schmitz V, Laudi S, Moeckel F, Puhl G, Stockmann M, Tran ZV, et al. Chronic renal dysfunction following liver transplantation. Clin Transplant 2008; 22: 333340.
  • 21
    Neau-Cransac M, Morel D, Bernard PH, Merville P, Revel P, Potaux L, Saric J. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal. Clin Transplant 2002; 16: 368373.
  • 22
    Poplawski S, Gonwa T, Goldstein R, Husberg B, Klintmalm G. Long term nephrotoxicity in liver transplantation. Transplant Proc 1989; 21: 24692471.
  • 23
    National Kidney Foundation Kidney Disease Outcome Quality Initiative Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation. Am J Kidney Dis 2002; 34: S1S266.
  • 24
    Griffiths MH, Crowe AV, Papadaki L, Banner NR, Yacoub MH, Thompson FD, Neild GH. Cyclosporin nephrotoxicity in heart and lung transplant patients. QJM 1996; 89: 751763.
  • 25
    Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9: 741747.
  • 26
    Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58: 170178.
  • 27
    Satchithananda DK, Parameshwar J, Sharples L, Taylor GJ, McNeil K, Wallwork J, Large SR. The incidence of end-stage renal failure in 17 years of heart transplantation: a single center experience. J Heart Lung Transplant 2002; 21: 651657.
  • 28
    Veillon S, Caillard S, Epailly E, Eisenmann B, Hannedouche T, Moulin B. Chronic renal failure after cardiac transplantation: predictive factors and influence on mortality—results of a monocenter study in 141 patients. Transplant Proc 2002; 34: 28192820.
  • 29
    D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217231.
  • 30
    Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 9196.
  • 31
    Weismuller TJ, Prokein J, Becker T, Barg-Hock H, Klempnauer J, Manns MP, Strassburg CP. Prediction of survival after liver transplantation by pre-transplant parameters. Scand J Gastroenterol 2008; 43: 736746.
  • 32
    Hampel H, Bynum GD, Zamora E, El-Serag HB. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001; 96: 22062210.
    Direct Link:
  • 33
    Wu CC, Yeung LK, Tsai WS, Tseng CF, Chu P, Huang TY, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol 2006; 65: 2833.
  • 34
    Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol 2007; 13: 55525559.
  • 35
    Moreau R, Labrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21: 111123.
  • 36
    Munoz SJ. The hepatorenal syndrome. Med Clin North Am 2008; 92: 813837, viii–ix.
  • 37
    Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 14931502.
  • 38
    Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403409.
  • 39
    Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818824.
  • 40
    Uriz J, Gines P, Cardenas A, Sort P, Jiminez W, Salmeron JM. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2001; 33: 4348.
  • 41
    Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941948.
  • 42
    Lim JK, Groszmann RJ. Vasoconstrictor therapy for the hepatorenal syndrome. Gastroenterology 2008; 134: 16081611.
  • 43
    Davis CL. Impact of pretransplant renal failure: when is listing for kidney-liver indicated? Liver Transpl 2005; 11: S35S44.
  • 44
    Krag A, Moller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007; 46: 18631871.
  • 45
    Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288295.
  • 46
    Mitzner S, Stange J, Klammt S, Risler T, Erley C, Bader B. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomized, controlled clinical trial. Liver Transpl 2000; 6: 277286.
  • 47
    Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, Kaplan RM. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001; 60: 11541163.
  • 48
    Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164176.
  • 49
    Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 13101318.
  • 50
    Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229236.
  • 51
    Terra C, Guevara M, Torre A, Gilabert R, Fernandez J, Martin-Llahi M, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129: 19441953.
  • 52
    Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45: 223229.
  • 53
    Cardenas A, Gines P, Uriz J, Bessa X, Salmeron JM, Mas A, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001; 34: 671676.
  • 54
    Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41: 12821289.
  • 55
    Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 13601368.
  • 56
    Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 13521359.
  • 57
    Nazar A, Guevara M, Marinelli M. Predictive factors of response to therapy in patients with cirrhosis and hepatorenal syndrome treated with terlipressin and albumin. Hepatology 2008; 48: 1682A.
  • 58
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 16901697.
  • 59
    Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 5564.
  • 60
    Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374380.
  • 61
    Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499505.
  • 62
    Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416422.
  • 63
    Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 18391847.
  • 64
    Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124: 634641.
  • 65
    Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005; 68: 362370.
  • 66
    Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361365.
  • 67
    Ruiz R, Kunitake H, Wilkinson AH, Danovitch GM, Farmer DG, Ghobrial RM, et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141: 735741; discussion 741–732.
  • 68
    Jeyarajah DR, Gonwa TA, McBride M, Testa G, Abbasoglu O, Husberg BS, et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 1997; 64: 17601765.
  • 69
    Locke JE, Warren DS, Singer AL, Segev DL, Simpkins CE, Maley WR, et al. Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts. Transplantation 2008; 85: 935942.
  • 70
    Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant 2008; 8: 22432251.
  • 71
    Ruiz R, Barri YM, Jennings LW, Chinnakotla S, Goldstein RM, Levy MF, et al. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl 2007; 13: 838843.
  • 72
    Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35: 11791185.
  • 73
    Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140146.
  • 74
    Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91: 21442149.
  • 75
    Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 2006; 70: 19141919.
  • 76
    Shihab FS, Andoh TF, Tanner AM, Yi H, Bennett WM. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999; 56: 21472159.
  • 77
    Shihab FS, Andoh TF, Tanner AM, Noble NA, Border WA, Franceschini N, Bennett WM. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 11411151.
  • 78
    Xin J, Homma T, Matsusaka T, Ma J, Isaka Y, Imai E, Ichikawa I. Suppression of cyclosporine a nephrotoxicity in vivo by transforming growth factor beta receptor-immunoglobulin G chimeric protein. Transplantation 2004; 77: 14331442.
  • 79
    Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002; 2: 111119.
  • 80
    Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52: 660673.
  • 81
    Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 2007; 293: F2F9.
  • 82
    Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity. Am J Transplant 2003; 3: 15501559.
  • 83
    Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Meria P, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006; 70: 10191025.
  • 84
    Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65: 12621271.
  • 85
    Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 5562.
  • 86
    Capron A, Lerut J, Verbaandert C, Mathys J, Ciccarelli O, Vanbinst R, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther Drug Monit 2007; 29: 340348.
  • 87
    Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661674.
  • 88
    Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 15011511.
  • 89
    Textor SC, Wilson DJ, Lerman A, Romero JC, Burnett JC Jr, Wiesner R, et al. Renal hemodynamics, urinary eicosanoids, and endothelin after liver transplantation. Transplantation 1992; 54: 7480.
  • 90
    Textor SC, Burnett JC Jr, Romero JC, Canzanello VJ, Taler SJ, Wiesner R, et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 1995; 47: 14261433.
  • 91
    Perico N, Ruggenenti P, Gaspari F, Mosconi L, Benigni A, Amuchastegui CS, et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54: 5660.
  • 92
    Sander M, Victor RG. Hypertension after cardiac transplantation: pathophysiology and management. Curr Opin Nephrol Hypertens 1995; 4: 443451.
  • 93
    Cohen AJ, Stegall MD, Rosen CB, Wiesner RH, Leung N, Kremers WK, Zein NN. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002; 8: 916921.
  • 94
    Wadei HM, Geiger XJ, Cortese C, Mai ML, Kramer DJ, Rosser BG, et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant 2008; 8: 26182626.
  • 95
    Campbell MS, Kotlyar DS, Brensinger CM, Lewis JD, Shetty K, Bloom RD, et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 2005; 11: 10481055.
  • 96
    Elzinga LW, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake. J Am Soc Nephrol 1993; 4: 214221.
  • 97
    De Nicola L, Thomson SC, Wead LM, Brown MR, Gabbai FB. Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 1993; 92: 18591865.
  • 98
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005; 24: 21292136.
  • 99
    Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809817.
  • 100
    Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514522.
  • 101
    Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 25622575.
  • 102
    Abramowicz D, Hadaya K, Hazzan M, Broeders N, Hoang AD, Ghisdal L, et al. Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. Nephrol Dial Transplant 2008; 23: 37273729.
  • 103
    Aliabadi AZ, Pohanka E, Seebacher G, Dunkler D, Kammerstatter D, Wolner E, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008; 8: 854861.
  • 104
    Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006; 6: 26512659.
  • 105
    Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 19341939.
  • 106
    Feutren G, Miller C. Low predictive value of cyclosporine level for efficacy or renal dysfunction in psoriasis and idiopathic nephrotic syndrome. Transplant Proc 1990; 22: 12991302.
  • 107
    Bach JF, Feutren G, Noel LH, Hannedouche T, Landais P, Timsit J, et al. Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels. Transplant Proc 1990; 22: 12961298.
  • 108
    Farkas SA, Schnitzbauer AA, Kirchner G, Obed A, Banas B, Schlitt HJ. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int 2009; 22: 4960.
  • 109
    Alexander JW, Goodman HR, Cardi M, Austin J, Goel S, Safdar S, et al. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int 2006; 19: 295302.
  • 110
    Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004; 18: 463472.
  • 111
    Davis CL, Gonwa TA, Wilkinson AH. Identification of patients best suited for combined liver-kidney transplantation: part II. Liver Transpl 2002; 8: 193211.
  • 112
    Brown RS Jr, Lombardero M, Lake JR. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996; 62: 17881793.
  • 113
    Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 2003; 41: 269278.
  • 114
    Herrero JI, Quiroga J, Sangro B, Girala M, Gomez-Manero N, Pardo F, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999; 5: 414420.
  • 115
    Chan CY, DasGupta K, Baker AL. Cyclosporin A: drug discontinuation for the management of long-term toxicity after liver transplantation. Hepatology 1996; 24: 10851089.
  • 116
    Pageaux GP, Rostaing L, Calmus Y, Duvoux C, Vanlemmens C, Hardgwissen J, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006; 12: 17551760.
  • 117
    Dale C, Marotta P. Continuous improvement in measured GFR with tapering CNI and the introduction of MMF in liver transplant recipients. Can J Gastroenterol 2008; 22: 4445.
  • 118
    Orlando G, Baiocchi L, Cardillo A, Iaria G, De Liguori Carino N, De Luca L, et al. Switch to 1.5 g MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007; 13: 4654.
  • 119
    Bilbao I, Castells L, Rojas L, Cancino J, Dopazo C, Castro E, et al. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol 2006; 6: 19771983.
  • 120
    Creput C, Blandin F, Deroure B, Roche B, Saliba F, Charpentier B, et al. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl 2007; 13: 10041010.
  • 121
    Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587591.
  • 122
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13: 16941702.
  • 123
    Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 10791085.
  • 124
    Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 126129.
  • 125
    Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005; 353: 20882089.
  • 126
    Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007; 13: 658664.
  • 127
    Sher L, Marotta P, Teperman A. Spare-the-Nephron trial in liver transplant recipients: interim efficacy and safety of mycophenolate mofetil/sirolimus maintenance therapy after CNI withdrawal [abstract]. Am J Transplant 2008; 8: 867871.
  • 128
    Tzakis AG, Tryphonopoulos P, Kato T, Nishida S, Levi DM, Madariaga JR, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77: 12091214.
  • 129
    Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11: 10641072.
  • 130
    Soliman T, Hetz H, Burghuber C, Gyori G, Silberhumer G, Steininger R, et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007; 13: 10391044.
  • 131
    Kootte AM, Lensen LM, van Bockel JH, van Es LA, Paul LC. High- and low-dose regimens of cyclosporin in renal transplantation: immunosuppressive efficacy and side-effects. Nephrol Dial Transplant 1988; 3: 666670.
  • 132
    Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 15761581.
  • 133
    Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 3947.
  • 134
    Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307313.
  • 135
    Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant 2007; 7: 518526.
  • 136
    Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 2000; 20: 126147.
  • 137
    Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006; 81: 643654.
  • 138
    Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 30153026.
  • 139
    Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 2006; 16: 148157.
  • 140
    Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 23262333.
  • 141
    Rush D, Arlen D, Boucher A, Busque S, Cockfield SM, Girardin C, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007; 7: 25382545.
  • 142
    Meier-Kriesche HU, Steffen BJ, Chu AH, Loveland JJ, Gordon RD, Morris JA, Kaplan B. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004; 4: 20582066.
  • 143
    Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 22732280.
  • 144
    Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 10701076.
  • 145
    Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883892.
  • 146
    Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006; 82: 6268.
  • 147
    Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 12821287.
  • 148
    Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770781.
  • 149
    Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7: 560570.
  • 150
    Flechner S, Cockfield S, Grinyo J. A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with tacrolimus (TAC) + mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2-year safety results from the ORION trial. Am J Transplant 2008; 9: 254.
  • 151
    Pearson T, Mulgaonkar S, Patel A. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare-the-Nephron (STN) trial. Am J Transplant 2008; 8: 213.
  • 152
    Birnbaum L, Limpan M, Paraskevas S. Management of chronic allograft nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4: 860865.
  • 153
    Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 37553762.
  • 154
    ClinicalTrials.gov. Available at: http://clinicaltrials.gov. Accessed June 2009.
  • 155
    Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876883.
  • 156
    Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008; 8: 19721981.
  • 157
    Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. Semin Liver Dis 2006; 26: 201210.
  • 158
    Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007; 7: 17701777.
  • 159
    Shapira MY, Abdul-Hai A, Resnick IB, Bitan M, Tsirigotis P, Aker M, et al. Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant 2009; 43: 339343.
  • 160
    De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 2009; 22: 279286.
  • 161
    Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 13961399.
  • 162
    Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003; 14: 21992210.
  • 163
    Byrick RJ, Rose DK. Pathophysiology and prevention of acute renal failure: the role of the anaesthetist. Can J Anaesth 1990; 37: 457467.
  • 164
    Dupont J, Messiant F, Declerck N, Tavernier B, Jude B, Durinck L, et al. Liver transplantation without the use of fresh frozen plasma. Anesth Analg 1996; 83: 681686.
  • 165
    Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553558.
  • 166
    Massicotte L, Lenis S, Thibeault L, Sassine MP, Seal RF, Roy A. Reduction of blood product transfusions during liver transplantation. Can J Anaesth 2005; 52: 545546.
  • 167
    Massicotte L, Lenis S, Thibeault L, Sassine MP, Seal RF, Roy A. Effect of low central venous pressure and phlebotomy on blood product transfusion requirements during liver transplantations. Liver Transpl 2006; 12: 117123.
  • 168
    Beltran J, et al. Paper presented at: 14th Congress of International Liver Transplantation Society; 2008; Paris, France.
  • 169
    Grande L, Rimola A, Cugat E, Alvarez L, Garcia-Valdecasas JC, Taura P, et al. Effect of venovenous bypass on perioperative renal function in liver transplantation: results of a randomized, controlled trial. Hepatology 1996; 23: 14181428.
  • 170
    Gonzalez FX, Garcia-Valdecasas JC, Grande L, Pacheco JL, Cugat E, Fuster J, et al. Vena cava vascular reconstruction during orthotopic liver transplantation: a comparative study. Liver Transpl Surg 1998; 4: 133140.
  • 171
    Parrilla P, Sanchez-Bueno F, Figueras J, Jaurrieta E, Mir J, Margarit C, et al. Analysis of the complications of the piggy-back technique in 1,112 liver transplants. Transplantation 1999; 67: 12141217.
  • 172
    Cirera I, Navasa M, Rimola A, Garcia-Pagan JC, Grande L, Garcia-Valdecasas JC, et al. Ascites after liver transplantation. Liver Transpl 2000; 6: 157162.
  • 173
    Figueras J, Llado L, Ramos E, Jaurrieta E, Rafecas A, Fabregat J, et al. Temporary portocaval shunt during liver transplantation with vena cava preservation. Results of a prospective randomized study. Liver Transpl 2001; 7: 904911.
  • 174
    Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358: 784793.
  • 175
    Ruggeberg A, Boehm S, Napieralski A. Development of a risk stratification model for predicting acute renal failure in orthotopic liver transplantation recipients. Anesthesia 2008; 63: 1741180.
  • 176
    Bellomo R, Wan L, May C. Vasoactive drugs and acute kidney injury. Crit Care Med 2008; 36: S179S186.
  • 177
    Zaky A, Pretto EA Jr, Earle SA, Piraccini E, Zuccarelli JE, Arheart KL, Proctor KG. Hemodynamic and metabolic efficacy of dopamine versus norepinephrine in a brain-dead swine model. Liver Transpl 2008; 14: 12661272.
  • 178
    Zacharias M, Gilmore IC, Herbison GP, Sivalingam P, Walker RJ. Interventions for protecting renal function in the perioperative period. Cochrane Database Syst Rev 2005:CD003590.
  • 179
    Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510524.
  • 180
    Swygert TH, Roberts LC, Valek TR, Brajtbord D, Brown MR, Gunning TC, et al. Effect of intraoperative low-dose dopamine on renal function in liver transplant recipients. Anesthesiology 1991; 75: 571576.
  • 181
    Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med 2002; 28: 877883.
  • 182
    Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit Care Resusc 2007; 9: 6068.
  • 183
    Polson RJ, Park GR, Lindop MJ, Farman JV, Calne RY, Williams R. The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. Anaesthesia 1987; 42: 1519.
  • 184
    Dohler KD, Meyer M. Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage. Best Pract Res Clin Anaesthesiol 2008; 22: 335350.
  • 185
    Landoni G, Biondi-Zoccai GG, Marino G, Bove T, Fochi O, Maj G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2008; 22: 2733.
  • 186
    Biancofiore G, Della Rocca G, Bindi L, Romanelli A, Esposito M, Meacci L, et al. Use of fenoldopam to control renal dysfunction early after liver transplantation. Liver Transpl 2004; 10: 986992.
  • 187
    Hadengue A, Moreau R, Bacq Y, Gaudin C, Braillon A, Lebrec D. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study. Hepatology 1991; 13: 111116.
  • 188
    Tumlin JA, Finkel K, Murray P. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007; 49: 5668.
  • 189
    Fontana I, Germi MR, Beatini M, Fontana S, Bertocchi M, Porcile E, et al. Dopamine “renal dose” versus fenoldopam mesylate to prevent ischemia-reperfusion injury in renal transplantation. Transplant Proc 2005; 37: 24742475.
  • 190
    Maerz L, Kaplan LJ. Abdominal compartment syndrome. Crit Care Med 2008; 36: S212S215.
  • 191
    Hynninen MS, Niemi TT, Poyhia R, Raininko EI, Salmenpera MT, Lepantalo MJ, et al. N-acetylcysteine for the prevention of kidney injury in abdominal aortic surgery: a randomized, double-blind, placebo-controlled trial. Anesth Analg 2006; 102: 16381645.
  • 192
    Haase M, Haase-Fielitz A, Bagshaw SM, Reade MC, Morgera S, Seevenayagam S, et al. Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med 2007; 35: 13241331.
  • 193
    Burns KE, Chu MW, Novick RJ, Fox SA, Gallo K, Martin CM, et al. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing CABG surgery: a randomized controlled trial. JAMA 2005; 294: 342350.
  • 194
    de Araujo M, Andrade L, Coimbra TM, Rodrigues AC Jr, Seguro AC. Magnesium supplementation combined with N-acetylcysteine protects against postischemic acute renal failure. J Am Soc Nephrol 2005; 16: 33393349.
  • 195
    Lang JD Jr, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 2007; 117: 25832591.
  • 196
    Barber K, Blackwell J, Collett D, Neuberger J. Life expectancy of adult liver allograft recipients in the UK. Gut 2007; 56: 279282.
  • 197
    Starzl TE, Iwatsuki S, Shaw BW Jr, Gordon RD, Esquivel CO. Immunosuppression and other nonsurgical factors in the improved results of liver transplantation. Semin Liver Dis 1985; 5: 334343.
  • 198
    Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study. Am J Transplant 2009; 9: 327336.
  • 199
    Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357: 609610.
  • 200
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 2008; 14: 651659.
  • 201
    Campbell KM, Yazigi N, Ryckman FC, Alonso M, Tiao G, Balistreri WF, et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 2006; 148: 475480.
  • 202
    Sandborn WJ, Hay JE, Porayko MK, Gores GJ, Steers JL, Krom RA, Wiesner RH. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 19: 925932.
  • 203
    Ramos HC, Reyes J, Abu-Elmagd K, Zeevi A, Reinsmoen N, Tzakis A, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995; 59: 212217.
  • 204
    Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63: 243249.
  • 205
    Devlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, Williams R. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926933.
  • 206
    Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449454.
  • 207
    Oike F, Yokoi A, Nishimura E, Ogura Y, Fujimoto Y, Kasahara M, et al. Complete withdrawal of immunosuppression in living donor liver transplantation. Transplant Proc 2002; 34: 1521.
  • 208
    Pons JA, Yelamos J, Ramirez P, Oliver-Bonet M, Sanchez A, Rodriguez-Gago M, et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 2003; 75: 10451047.
  • 209
    Tryphonopoulos P, Tzakis AG, Weppler D, Garcia-Morales R, Kato T, Madariaga JR, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 2005; 5: 608613.
  • 210
    Eason JD, Cohen AJ, Nair S, Alcantera T, Loss GE. Tolerance: is it worth the risk? Transplantation 2005; 79: 11571159.
  • 211
    Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44: 702709.
  • 212
    Assy N, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation 2007; 83: 15711576.
  • 213
    Li Y, Koshiba T, Yoshizawa A, Yonekawa Y, Masuda K, Ito A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 21182125.
  • 214
    Koshiba T, Li Y, Takemura M, Wu Y, Sakaguchi S, Minato N, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007; 17: 9497.
  • 215
    Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 2008; 20: 4347.
  • 216
    Tzakis A, Tryphonopoulos P, Weppler D, Garcia-Morales R, Cirocco R. Operational tolerance: long term observations after complete withdrawal of immunosuppression (ISP) in liver transplant recipients. Am J Transplant 2008; 8(suppl 2): 542.
  • 217
    Martinez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, Rimola A, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309319.
  • 218
    Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 28452857.
  • 219
    Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 10181026.
  • 220
    Carbone J, Micheloud D, Salcedo M, Rincon D, Banares R, Clemente G, et al. Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection. Transpl Infect Dis 2008; 10: 396402.
  • 221
    Propst-Graham KL, Preheim LC, Vander Top EA, Snitily MU, Gentry-Nielsen MJ. Cirrhosis-induced defects in innate pulmonary defenses against Streptococcus pneumoniae. BMC Microbiol 2007; 7: 94.
  • 222
    Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey MR. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994; 20: 362369.
  • 223
    Kastelan S, Ljubicic N, Kastelan Z, Ostojic R, Uravic M. The role of duplex-Doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis. Hepatogastroenterology 2004; 51: 14081412.
  • 224
    Davis CL, Feng S, Sung R, Wong F, Goodrich NP, Melton LB, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007; 7: 17021709.
  • 225
    Ueno T, Barri YM, Netto GJ, Martin A, Onaca N, Sanchez EQ, et al. Liver and kidney transplantation for polycystic liver and kidney-renal function and outcome. Transplantation 2006; 82: 501507.
  • 226
    Pichler R, Dittrich M, Anderson A, Kendrick E, Crithers R, Larson A. Prediction of benefit from simultaneous liver kidney transplantation versus liver alone transplantation: potential role for native kidney biopsy. J Am Soc Nephrol 2006; 17: 795A.
  • 227
    Wolfe RA, McCullough KP, Schaubel DE, Kalbfleisch JD, Murray S, Stegall MD, Leichtman AB. Calculating life years from transplant (LYFT): methods for kidney and kidney-pancreas candidates. Am J Transplant 2008; 8: 9971011.